Developer docs
API playgroundTry for free, no card

Search company profiles

Altan Pharma

Full company profile

uuid000ftfy

Namestring
Altan Pharma
Legal namestring
Altan Pharmaceuticals, S.A.
Websiteurl
altanpharma.eu
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Altan Pharma (Altan Pharmaceuticals, S.A.) is a specialty pharmaceutical company that develops, manufactures, and markets injectable medicines for hospital use, with a focus on Central Nervous System (CNS) conditions including severe pain management and addiction treatment. The company's core product portfolio includes Recivit (fentanyl-based treatment for intense pain), Nefopam 20 mg/2 ml injectable solution (an analgesic for moderate to severe pain), and a range of CNS medications and hospital injectables. Altan Pharma operates as a wholly-owned subsidiary of Ethypharm Group, a European specialty pharmaceutical company with operations across Spain, France, Germany, the United Kingdom, and China.

The company's business model is built on B2B pharmaceutical distribution to hospitals and healthcare providers through established pharmaceutical wholesale networks, primarily within Spain. Altan Pharma expands its product portfolio through licensing agreements with partners such as Medochemie (for Nefopam in Spain) and leverages Ethypharm Group's pan-European infrastructure for geographic reach. The company is currently investing in production capacity expansion in Spain, supported by EU FEDER regional incentive funding. Revenue mechanics are not publicly disclosed, but the company generates income through product sales of specialty injectable medicines in the hospital channel. The company's go-to-market relies on direct sales to institutional healthcare buyers and licensing partnerships to broaden therapeutic coverage in pain management and addiction treatment.

Altan Pharma maintains a focused differentiation strategy centered on domain specialization in CNS and hospital injectable therapeutics - areas with high regulatory barriers and limited competition. The company actively pursues business development partnerships to address unmet medical needs in severe pain management, and its parent Ethypharm Group positions the entity for continued portfolio expansion through licensing and geographic extension across European markets.

Short descriptiontext

Altan Pharma is a specialty pharmaceutical company and subsidiary of Ethypharm Group that develops, manufactures, and markets injectable medicines for hospital use, focusing on CNS conditions including severe pain management and addiction treatment across European markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersDún Laoghaire, Ireland
HQ citystring
Dún Laoghaire
HQ countrystring
Ireland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, hospital injectables, CNS medications, pain management drugs, injectable medicines
Industry3 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Injectable Pharmaceuticals
Social media profiles1 record
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Altan Pharma develops, manufactures, and markets specialty injectable pharmaceutical medicines focused on Central Nervous System (CNS) conditions and hospital injectables. The portfolio addresses severe pain management and addiction, including fentanyl-based treatments (Recivit) and analgesic injectable solutions (Nefopam 20 mg/2 ml). The company operates as part of the Ethypharm Group, commercializing products primarily in Spain and broader European markets through licensing agreements and pharmaceutical distribution networks.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Altan Pharma (Altan Pharmaceuticals, S.A.) is a company within the Ethypharm Group, a European pharmaceutical company specializing in Central Nervous System (CNS) conditions and Hospital Injectables. Products include treatments for severe pain and addiction. The company operates within the broader Ethypharm portfolio, which also commercializes products like Recivit (fentanyl) for intense pain and Nefopam injectable solutions through regional partnerships.

Partnership1 partner
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Ethypharm Iberia signed a licensing agreement with Medochemie to commercialize Nefopam 20 mg/2 ml injectable solution in Spain. This analgesic provides effective treatment for moderate to severe pain, addressing real needs for new therapeutic options in the Spanish market. This agreement supports Ethypharm's ambition to expand its portfolio of essential medicines.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

European specialty pharma company focused on pain management. Previously distributed Recivit in France before it returned to Ethypharm's portfolio in April 2025, making it a directly comparable specialty pain player competing for the same therapeutic area and customer base.

TypeDirect peer
Description

Cyprus-based global generic and specialty pharmaceutical manufacturer that signed the licensing agreement with Ethypharm Iberia for Nefopam injectable in Spain. Directly comparable as a producer of injectable finished dosage forms targeting similar hospital customers.

TypeDirect peer
Description

Specialty pharmaceutical company with a portfolio in hospital injectables, pain management, and addiction therapies. Comparable in therapeutic focus (CNS, severe pain) and in delivering injectable specialty products to hospital channels.

TypeDirect peer
Description

Specialty pharmaceutical company focused on addiction treatment and CNS disorders. Directly comparable as a CNS-focused player addressing the same addiction-therapy use case that Altan serves alongside severe pain.

TypeDirect peer
Description

European specialty manufacturer of hospital injectable medicines, part of the Aenova Group. Closely aligned with Altan's hospital-injectables focus, serving similar hospital pharmacy and clinical customers with finished injectable preparations.

TypeDirect peer
Description

Global specialty pharmaceutical company with a substantial injectable generics business serving hospital customers. Comparable as a manufacturer of injectable finished dosage forms across European and global markets, with similar GTM into hospital channels.

7Recipharm
TypeDirect peer
Description

European pharmaceutical contract development and manufacturing organization with strong sterile injectable capabilities. Comparable as a European-based producer of injectable pharmaceutical preparations serving hospital and specialty pharma customers.

TypeEmerging player
Description

Swedish specialty pharmaceutical company developing CNS therapies using advanced drug delivery. Comparable as a CNS-focused specialty pharma peer, though more research-stage and narrower in indications than Altan's hospital-injectables franchise.

TypeBroad incumbent
Description

Global medical technology and pharmaceutical company supplying hospital injectable solutions, infusion therapy, and related products. A broader incumbent that overlaps with Altan in hospital injectable supply, though across a much wider product portfolio.

TypeOthers
Description

Parent group of Altan Pharma and itself a European specialty pharma in CNS and hospital injectables. Relevant as the controlling parent whose strategic direction and capital allocation shape Altan's opportunity set and as a direct reference point for size and scope.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Altan Pharma

Specialty Injectable Pharmaceuticalsaltanpharma.eu

Altan Pharma is a specialty pharmaceutical company and subsidiary of Ethypharm Group that develops, manufactures, and markets injectable medicines for hospital use, focusing on CNS conditions including severe pain management and addiction treatment across European markets.

What Altan Pharma does

Altan Pharma (Altan Pharmaceuticals, S.A.) is a specialty pharmaceutical company that develops, manufactures, and markets injectable medicines for hospital use, with a focus on Central Nervous System (CNS) conditions including severe pain management and addiction treatment. The company's core product portfolio includes Recivit (fentanyl-based treatment for intense pain), Nefopam 20 mg/2 ml injectable solution (an analgesic for moderate to severe pain), and a range of CNS medications and hospital injectables. Altan Pharma operates as a wholly-owned subsidiary of Ethypharm Group, a European specialty pharmaceutical company with operations across Spain, France, Germany, the United Kingdom, and China.

The company's business model is built on B2B pharmaceutical distribution to hospitals and healthcare providers through established pharmaceutical wholesale networks, primarily within Spain. Altan Pharma expands its product portfolio through licensing agreements with partners such as Medochemie (for Nefopam in Spain) and leverages Ethypharm Group's pan-European infrastructure for geographic reach. The company is currently investing in production capacity expansion in Spain, supported by EU FEDER regional incentive funding. Revenue mechanics are not publicly disclosed, but the company generates income through product sales of specialty injectable medicines in the hospital channel. The company's go-to-market relies on direct sales to institutional healthcare buyers and licensing partnerships to broaden therapeutic coverage in pain management and addiction treatment.

Altan Pharma maintains a focused differentiation strategy centered on domain specialization in CNS and hospital injectable therapeutics - areas with high regulatory barriers and limited competition. The company actively pursues business development partnerships to address unmet medical needs in severe pain management, and its parent Ethypharm Group positions the entity for continued portfolio expansion through licensing and geographic extension across European markets.

Altan Pharma firmographics

Firmographics
Name
Altan Pharma
Legal name
Altan Pharmaceuticals, S.A.
Website
https://altanpharma.eu
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
101–250 employees
Short description
Altan Pharma is a specialty pharmaceutical company and subsidiary of Ethypharm Group that develops, manufactures, and markets injectable medicines for hospital use, focusing on CNS conditions including severe pain management and addiction treatment across European markets.
Ownership category
akta.pro rank

Altan Pharma industry classification

Industry
Product category
Specialty Injectable Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Specialty pharmaceuticals
  • Hospital injectables
  • CNS medications
  • Pain management drugs
  • Injectable medicines

Where Altan Pharma is headquartered

Location

Headquarters

HQ city
Dún Laoghaire
HQ country
Ireland
HQ region
Europe

Offices1 record

Markets served

Altan Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales

Distribution channels1 record

Marketing channels1 record

Altan Pharma product offering

Product offering

Core offering

Altan Pharma develops, manufactures, and markets specialty injectable pharmaceutical medicines focused on Central Nervous System (CNS) conditions and hospital injectables. The portfolio addresses severe pain management and addiction, including fentanyl-based treatments (Recivit) and analgesic injectable solutions (Nefopam 20 mg/2 ml). The company operates as part of the Ethypharm Group, commercializing products primarily in Spain and broader European markets through licensing agreements and pharmaceutical distribution networks.

Product overview

Altan Pharma (Altan Pharmaceuticals, S.A.) is a company within the Ethypharm Group, a European pharmaceutical company specializing in Central Nervous System (CNS) conditions and Hospital Injectables. Products include treatments for severe pain and addiction. The company operates within the broader Ethypharm portfolio, which also commercializes products like Recivit (fentanyl) for intense pain and Nefopam injectable solutions through regional partnerships.

Differentiator

Problem solved

Functional benefit

Companies that use Altan Pharma

Customer profile

Segments2 records

Ideal customer profiles1 record

Altan Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Altan Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • MedochemiecoreOEM/ Whitelabel/ Licensing PartnerEthypharm Iberia signed a licensing agreement with Medochemie to commercialize Nefopam 20 mg/2 ml injectable solution in Spain. This analgesic provides effective treatment for moderate to severe pain, addressing real needs for new therapeutic options in the Spanish market. This agreement supports Ethypharm's ambition to expand its portfolio of essential medicines.

Recent moves6 records

Expansion highlights4 records

Altan Pharma competitors and assessment

Company assessment

Direct peers

  • Grünenthal: European specialty pharma company focused on pain management. Previously distributed Recivit in France before it returned to Ethypharm's portfolio in April 2025, making it a directly comparable specialty pain player competing for the same therapeutic area and customer base.
  • Medochemie: Cyprus-based global generic and specialty pharmaceutical manufacturer that signed the licensing agreement with Ethypharm Iberia for Nefopam injectable in Spain. Directly comparable as a producer of injectable finished dosage forms targeting similar hospital customers.
  • Mallinckrodt Pharmaceuticals: Specialty pharmaceutical company with a portfolio in hospital injectables, pain management, and addiction therapies. Comparable in therapeutic focus (CNS, severe pain) and in delivering injectable specialty products to hospital channels.
  • Indivior: Specialty pharmaceutical company focused on addiction treatment and CNS disorders. Directly comparable as a CNS-focused player addressing the same addiction-therapy use case that Altan serves alongside severe pain.
  • Hameln Pharmaceuticals: European specialty manufacturer of hospital injectable medicines, part of the Aenova Group. Closely aligned with Altan's hospital-injectables focus, serving similar hospital pharmacy and clinical customers with finished injectable preparations.
  • Hikma Pharmaceuticals: Global specialty pharmaceutical company with a substantial injectable generics business serving hospital customers. Comparable as a manufacturer of injectable finished dosage forms across European and global markets, with similar GTM into hospital channels.
  • Recipharm: European pharmaceutical contract development and manufacturing organization with strong sterile injectable capabilities. Comparable as a European-based producer of injectable pharmaceutical preparations serving hospital and specialty pharma customers.

Emerging players

  • Camurus: Swedish specialty pharmaceutical company developing CNS therapies using advanced drug delivery. Comparable as a CNS-focused specialty pharma peer, though more research-stage and narrower in indications than Altan's hospital-injectables franchise.

Broad incumbents

  • B. Braun: Global medical technology and pharmaceutical company supplying hospital injectable solutions, infusion therapy, and related products. A broader incumbent that overlaps with Altan in hospital injectable supply, though across a much wider product portfolio.

Others

  • Ethypharm Group: Parent group of Altan Pharma and itself a European specialty pharma in CNS and hospital injectables. Relevant as the controlling parent whose strategic direction and capital allocation shape Altan's opportunity set and as a direct reference point for size and scope.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Altan Pharma social profiles

Digital presence

Altan Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Altan Pharma leadership team

Management profile

Number of profiles

Altan Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Altan Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Altan Pharma

What does Altan Pharma do?

Altan Pharma develops, manufactures, and markets specialty injectable pharmaceutical medicines focused on Central Nervous System (CNS) conditions and hospital injectables. The portfolio addresses severe pain management and addiction, including fentanyl-based treatments (Recivit) and analgesic injectable solutions (Nefopam 20 mg/2 ml). The company operates as part of the Ethypharm Group, commercializing products primarily in Spain and broader European markets through licensing agreements and pharmaceutical distribution networks.

Is Altan Pharma a public or private company?

Altan Pharma is a private company. It is classified as corporate owned and is currently operating.

When was Altan Pharma founded?

Altan Pharma was founded in 2015. It employs 101 to 250 people.

Where is Altan Pharma based?

Altan Pharma is headquartered in Dún Laoghaire, Ireland, in the Europe region.

Who are Altan Pharma's main competitors?

Direct peers on record are Grünenthal, Medochemie, Mallinckrodt Pharmaceuticals, Indivior, Hameln Pharmaceuticals, Hikma Pharmaceuticals and Recipharm. Camurus is listed as an emerging player. B. Braun is listed as a broad incumbent. Ethypharm Group is listed as an others.

Does Altan Pharma have an API?

No public API is recorded for Altan Pharma.

What industry is Altan Pharma in?

Altan Pharma's product category is Specialty Injectable Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Les EchosEthypharm se déploie en Espagne grâce à Altan PharmaEthypharm has expanded into Spain by acquiring Altan Pharma for approximately €100 million. This acquisition follows Ethypharm's establishment of a subsidiary in Italy earlier in 2021 and allows the company to operate in its fifth European country, enhancing its portfolio focused on pain relief and addiction treatments.PR NewswireEthypharm to acquire Altan Pharma, entering the Spanish market and enhancing its Critical Care portfolio and R&D pipelineEthypharm, a French pharmaceutical company, has entered into a definitive agreement to acquire Altan Pharma, a specialty pharmaceutical company focused on injectable medicines for hospital use. The transaction will give Ethypharm full commercial coverage of the top 5 European markets and significantly expand its Critical Care franchise with an enlarged hospital injectable product portfolio and a rich R&D pipeline. The deal is expected to close in the second half of 2021, subject to customary conditions.RTE.ieMalin's Altan Pharma to be bought by EthypharmEthypharm has acquired Altan Pharma, a specialty pharmaceutical company, from its majority shareholder Malin Corporation for net proceeds of approximately €68 million. The transaction is subject to competition authority filings and is expected to close in the second half of the year. Malin intends to use the capital to repay debt and return value to shareholders.RTE.ieMalin buys stake in Altan PharmaMalin acquired a 65% stake in Irish drugmaker Altan Pharma for €34.5m, its second investment in two days. The Dublin-based private healthcare investor will enter the injectable drug market with Altan, which acquired Spanish injectable firms for €87.5m. Malin also invested $35m in US firm Melinta Therapeutics.GlobeNewswirePersonal Chemistry Offers Unique Professional Microwave Scale Up ServicesPersonal Chemistry announced a new microwave scale-up service for drug discovery, offering time savings. ALTANA Pharma synthesized 220g of a substance using the service, with reaction parameters transferred directly from small-scale instruments. The company provides custom synthesis from gram to kg scale.